Activity of benzimidazoles against Dientamoeba fragilis (Trichomonadida, Monocercomonadidae) in vitro and correlation of beta-tubulin sequences as an indicator of resistance.

Damien Stark, Joel L N Barratt, Tamalee Roberts, Deborah Marriott, John T Harkness, John Ellis

Open access · goldAbstract readComparative Study

In one paragraph

Article in Parasite (Paris, France), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it

0cells of the map it votes in

2citing papers in PubMed

0.9field-weighted citation impact, top 29% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

Paromomycin is superior to metronidazole in Dientamoeba fragilis treatment.International journal for parasitology. Drugs and drug resistance · 2019
Article
Dientamoeba fragilis, the Neglected Trichomonad of the Human Bowel.Clinical microbiology reviews · 2016
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Damien StarkDivision of Microbiology, SydPath, St. Vincent's Hospital, Darlinghurst, NSW 2010, Australia - University of Technology Sydney, School of Medical and Molecular Biosciences, Broadway 2007, Australia.

Joel L N BarrattUniversity of Technology Sydney, School of Medical and Molecular Biosciences, Broadway 2007, Australia - University of Technology Sydney, iThree Institute, Broadway 2007, Australia.

Tamalee RobertsDivision of Microbiology, SydPath, St. Vincent's Hospital, Darlinghurst, NSW 2010, Australia - University of Technology Sydney, School of Medical and Molecular Biosciences, Broadway 2007, Australia.

Deborah MarriottDivision of Microbiology, SydPath, St. Vincent's Hospital, Darlinghurst, NSW 2010, Australia - University of Technology Sydney, School of Medical and Molecular Biosciences, Broadway 2007, Australia.

John T HarknessDivision of Microbiology, SydPath, St. Vincent's Hospital, Darlinghurst, NSW 2010, Australia - University of Technology Sydney, School of Medical and Molecular Biosciences, Broadway 2007, Australia.

John EllisUniversity of Technology Sydney, School of Medical and Molecular Biosciences, Broadway 2007, Australia.

University of Technology Sydney · AUSt Vincent's Hospital Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, Dientamoeba fragilis has emerged as a significant and common enteropathogen. The majority of patients with dientamoebiasis present with gastrointestinal complaints and chronic symptoms are common. Numerous studies have successfully demonstrated parasite clearance, coupled with complete resolution of clinical symptoms following treatment with various antiparasitic compounds. Despite this, there is very little in vitro susceptibility data available for the organism. Benzimidazoles are a class of antiparasitic drugs that are commonly used for the treatment of protozoan and helminthic infections. Susceptibility testing was undertaken on four D. fragilis clinical isolates against the following benzimidazoles: albendazole, flubendazole, mebendazole, nocodazole, triclabendazole and thiabendazole. The activities of the antiprotozoal compounds at concentrations ranging from 2 μg/mL to 500 μg/mL were determined via cell counts of D. fragilis grown in xenic culture. All tested drugs showed no efficacy. The beta-tubulin transcript was sequenced from two of the D. fragilis isolates and amino acid sequences predicted a susceptibility to benzimidazoles. This is the first study to report susceptibility profiles for benzimidazoles against D. fragilis, all of which were not active against the organism. This study also found that beta-tubulin sequences cannot be used as a reliable marker for resistance of benzimidazoles in D. fragilis.

Indexed as

Amino Acid SequenceAntiprotozoal AgentsBenzimidazolesConsensus SequenceDientamoebaDrug ResistanceGenotypeIn Vitro TechniquesMolecular Sequence DataProtozoan ProteinsRNA, ProtozoanSequence AlignmentSequence Homology, Amino AcidSpecies SpecificityTranscriptomeTubulinAntiprotozoal AgentsBenzimidazolesProtozoan ProteinsRNA, ProtozoanTubulin

Identifiers

PMID25148459

DOI10.1051/parasite/2014043

PMCPMC4141546

OpenAlexW2107326820

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.